Cargando…

PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer

Gastric cancer (GC) is one of the main causes of cancer incidence rate and mortality worldwide. As the main breakthrough direction, the application of immune checkpoint inhibitors makes patients with GC have better prognosis, where PD-L1/PD-1 inhibitors in immunotherapy have good anti-tumor immune e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yingzi, Yang, Yan, Chen, Yiran, Lin, Wu, Chen, Xiangliu, Liu, Jin, Huang, Yingying, Wang, Haiyong, Teng, Lisong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729722/ https://www.ncbi.nlm.nih.gov/pubmed/36505487 http://dx.doi.org/10.3389/fimmu.2022.1060497

Ejemplares similares

EXOSC5 promotes proliferation of gastric cancer through regulating AKT/STAT3 signaling pathways
por: Chen, Xiangliu, et al.
Publicado: (2022)

Comprehensive Roles and Future Perspectives of Exosomes in Peritoneal Metastasis of Gastric Cancer
por: Chen, Xiangliu, et al.
Publicado: (2021)

MiR-301a-5p/SCIN promotes gastric cancer progression via regulating STAT3 and NF-κB signaling
por: Huang, Yingying, et al.
Publicado: (2021)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis
por: Lin, Wu, et al.
Publicado: (2023)

Microbiota and metabolites alterations in proximal and distal gastric cancer patients
por: Yang, Yan, et al.
Publicado: (2022)

Anti‐PD‐1/Her2 Bispecific Antibody IBI315 Enhances the Treatment Effect of Her2‐Positive Gastric Cancer through Gasdermin B‐Cleavage Induced Pyroptosis (Adv. Sci. 30/2023)
por: Lin, Wu, et al.
Publicado: (2023)

Host miRNAs-microbiota interactions in gastric cancer
por: Yang, Yan, et al.
Publicado: (2022)

ASF1b is a novel prognostic predictor associated with cell cycle signaling pathway in gastric cancer
por: Chen, Chuanzhi, et al.
Publicado: (2022)

Expression and Prognostic Value of Chromobox Family Proteins in Esophageal Cancer
por: Liu, Jin, et al.
Publicado: (2022)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

The Essential Factors of Establishing Patient-derived Tumor Model
por: Chen, Chuanzhi, et al.
Publicado: (2021)

Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
por: Xu, Yanxin, et al.
Publicado: (2022)

PN3b as an independent risk factor for poor prognosis and peritoneal recurrence in Borrmann type IV gastric cancer: A retrospective cohort study
por: Chen, Yiran, et al.
Publicado: (2022)

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
por: Wu, Yilun, et al.
Publicado: (2019)

PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer
por: Hu, Rui, et al.
Publicado: (2022)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
por: Yan, Huiyu, et al.
Publicado: (2023)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
por: Gu, Tingxuan, et al.
Publicado: (2023)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
por: Hu, Zhang-Wei, et al.
Publicado: (2022)

Case report: The MSI-L/p-MMR metastatic rectal cancer patient who failed systemic therapy responds to anti-PD-1 immunotherapy after stereotactic body radiation-therapy
por: Liu, Shijin, et al.
Publicado: (2022)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
por: Hou, Bo, et al.
Publicado: (2023)

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
por: Hudson, Katie, et al.
Publicado: (2020)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy
por: Feng, Chong, et al.
Publicado: (2023)

Role of regulation of PD-1 and PD-L1 expression in sepsis
por: Zhang, Teng, et al.
Publicado: (2023)

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective
por: Guo, Libin, et al.
Publicado: (2020)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
por: Zuazo, Miren, et al.
Publicado: (2020)

A d-peptide-based oral nanotherapeutic modulates the PD-1/PD-L1 interaction for tumor immunotherapy
por: Liu, Dan, et al.
Publicado: (2023)

A novel genomic classification system of gastric cancer via integrating multidimensional genomic characteristics
por: Wang, Haiyong, et al.
Publicado: (2021)

Anti–PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection–Related Advanced Hepatocellular Carcinoma: A Literature Review
por: Li, Bin, et al.
Publicado: (2020)

Artificial Intelligence-Assisted Score Analysis for Predicting the Expression of the Immunotherapy Biomarker PD-L1 in Lung Cancer
por: Cheng, Guoping, et al.
Publicado: (2022)

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
por: Li, Tianye, et al.
Publicado: (2023)

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD
por: Chen, Chuanzhi, et al.
Publicado: (2022)

Neoantigens Derived from Recurrently Mutated Genes as Potential Immunotherapy Targets for Gastric Cancer
por: Zhou, Jie, et al.
Publicado: (2019)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
por: Wang, Yuanyuan, et al.
Publicado: (2021)

Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis
por: Liu, Kewei, et al.
Publicado: (2022)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
por: Raftery, Martin J., et al.
Publicado: (2018)

A Novel PD-L1-Containing MSLN Targeting Vaccine for Lung Cancer Immunotherapy
por: Zeng, Wuyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d7pr837roiafu8jarrb4m7t3s4